Gland Pharma shares surge over 9% after December quarter profit rises 28%

Shares of Gland Pharma, the Hyderabad-based drug maker, surged as much as 9.32% to hit an intraday high of ₹1,847.10 on the National Stock Exchange (NSE) on Thursday, January 29 after it reported its December quarter earnings post market hours on Wednesday. On the BSE, Gland Pharma shares climbed as much as 9.5% to hit an intraday high of ₹1849 amid spike in trading activity.

The Hyderabad-based drug maker reported net profit of ₹261 crore in the third quarter of current financial year (Q3FY26), marking an increase of 28% from ₹205 crore in the same period last year.

Gland Pharma's revenue from operations rose 23% to ₹1,695 crore in October-December period from ₹1,384 crore in the year-ago period.

The company reported stable operational performance as its EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) also known as operating profit jumped 21% to ₹435 crore but its EBITDA margin contracted by 40 basis points to 25.65%.

“Our strong Q3 FY26 performance, driven by robust year-on-year revenue growth of 22% and healthy adj. EBITDA margin of 26%, reflects the disciplined execution across our businesses. We remain confident in sustaining this momentum as new product launches, CDMO contract ramp‑ups, and operational efficiencies continue to strengthen our trajectory,” said Srinivas Sadu, Executive Chairman of Gland Pharma.

During the quarter, Gland Pharma's investment on research and development (R&D) rose to ₹65 crore compared with ₹44 crore in the corresponding period last year. The company also launched nine molecules in the USA this quarter, including Argatroban, Acetazolamide and Doxycycline. There were two new launches in other regulated markets of Europe, Canada, Australia and New Zealand.

The company filed nine ANDAs in December quarter and four were approved contributing to a cumulative total of 384 ANDA filings in the United States.

Meanwhile, Gland Pharma shares were in very high demand as trading activity in the counter spiked. Trading volume on the NSE surged by over 20 times to 20.96 lakh shares compared with an average trading volume of 1.03 lakh shares.

On the BSE, as many as 1.66 lakh shares changed hands compared with an average of 3,056 shares traded daily in the past two weeks.

As of 11:10 am, Gland Pharma shares traded 6.82% higher at ₹1,806, outperforming the NIFTY Smallcap 100 index which was down 0.13%. The stock was among the top gainers in the NIFTY Smallcap 100 index.